New York, New York (PRWEB) May 20, 2014
A California woman has filed a hysterectomy cancer lawsuit http://www.gynecaremorcellatorlawsuit.com/ ) that alleges the use of a power morcellator during gynecological surgery caused an undiagnosed cancer within her uterus to spread throughout her body, Bernstein Liebhard LLP reports. According to the complaint, the Plaintiff was diagnosed with metastatic leiomyoscarcoma after undergoing a supracervical hysterectomy with a Wolf Power Morcellator in May 2012. The lawsuit, which was filed in the U.S. District Court, Northern District of California on May 13, 2014, alleges that the use of the morcellator promoted the dissemination of uterine cancer cells throughout her peritoneal cavity. The Plaintiff has since been found to have four small lesions in her lungs, which are suspected to be signs of spreading leiomyoscarcoma. She and her husband are both seeking compensatory and punitive damages from the Richard Wolf Medical Instruments Co. (Case No. Case5:14-cv-02209-PSG)
“The allegations contained in this morcellator lawsuit echo claims we have heard from numerous women who have contacted our Firm in the wake of a cancer diagnosis that followed uterine morcellation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering hysterectomy cancer lawsuit reviews to women who suffered uterine sarcoma or other cancers allegedly spread by morcellation.
Morcellator Lawsuit Allegations
According to court documents, the California morcellator lawsuit is one of several that have been filed on behalf of women whose uterine cancers were allegedly spread by morcellation. These devices are used during minimally-invasive hysterectomies and fibroid removals to shred tissue so that it may be removed from the body through a small abdominal incision. On April 17, 2014, a U.S. Food & Drug Administration (FDA) alert discouraged doctors from using the devices in laparoscopic hysterectomy and fibroid removals, because of the risk that they could promote the spread of undetected uterine sarcomas and other cancers. Roughly 1 in 350 women who undergo fibroid removal may also suffer from undiagnosed uterine cancers, the FDA said.
The FDA’s review of power morcellators is ongoing, and will culminate later this summer when it convenes a meeting of its Obstetrics and Gynecological Medical Device Advisory Committee. Shortly after the FDA issued its morcellator alert, Johnson & Johnson’s Ethicon unit announced it would suspend sales of its Gynecare Morcellex. Morcellex Sigma Tissue Morcellator System, and Gynecare X-Tract Tissue Morcellator products pending further guidance from the agency.* A number of hospitals, including the Cleveland Clinic, have also moved to bar or limit the technique until the FDA completes its review.**
Women who were diagnosed with cancer that was allegedly spread by a power morcellator may be entitled to compensation. To learn more about filing a hysterectomy cancer lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling 800-511-5092.
*reuters.com/article/2014/04/30/us-johnson-johnson-device-idUSKBN0DG06G20140430, Reuters, April 30, 2014
**cleveland.com/healthfit/index.ssf/2014/04/surgical_tool_for_hysterectomy.html, Cleveland Plain Dealer, April 28, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP